Is Islam Makhachev the greatest fighter of all time? | Khabib Nurmagomedov and Lex Fridman
Khabib Nurmagomedov discusses Islam Makhachev's potential to become the greatest MMA fighter of all time, comparing him to legendary fighters like GSP, Jon Jones, and Demetrious Johnson. While Khabib believes Islam has the capability to break records and surpass these greats, he expresses concern about the limited time remaining in his career, particularly noting how age affects performance more severely in lighter weight classes.
Summary
In this interview with Lex Fridman, Khabib Nurmagomedov addresses the question of whether Islam Makhachev can become the greatest MMA fighter of all time. Khabib clarifies that he himself never pursued the title of 'greatest' or 'number one,' instead focusing on becoming a world champion and proving himself within his sport. When discussing greatness in MMA, Khabib acknowledges that there are multiple legendary fighters in the conversation, including Georges St-Pierre, Demetrious Johnson, Jon Jones, Fedor Emelianenko, Cain Velasquez, and Daniel Cormier. He expresses that if people want to include him and Islam in this elite conversation, he would be satisfied with that outcome.
Regarding Islam's specific potential, Khabib asserts that if Jon Jones and Demetrious Johnson (who holds 11 title defenses) are part of the GOAT conversation, then Islam certainly could be as well. Khabib states his goal is for Islam to break all existing records and surpass fighters like Jon Jones, Demetrious Johnson, and St-Pierre. However, Khabib introduces a significant concern: time is becoming a limiting factor for Islam's career trajectory.
Khabib explains that the aging process affects fighters differently depending on their weight class. He notes that Jon Jones has had more flexibility by competing at both light heavyweight and heavyweight, where fighters can remain competitive even into their late 30s because the physical demands—particularly reaction speed—are less stringent than in lighter divisions. By contrast, Khabib emphasizes that competing at lightweight (155 lbs) and welterweight (170 lbs) divisions is much more age-sensitive. He argues that the difference in athletic capability between a 32-year-old and a 38-year-old fighter is dramatic in these lighter weight classes, and this biological reality will become increasingly important for Islam's legacy trajectory.
Key Insights
- Khabib states he never pursued becoming the 'greatest of all time' and instead focused solely on becoming a world champion and proving himself in his sport
- Khabib argues that if Jon Jones and Demetrious Johnson (with 11 title defenses) can be in the GOAT conversation, Islam should have the same opportunity to be included
- Khabib expresses concern that Islam's window of opportunity is narrowing because time affects lighter weight class competitors more severely than heavier weight class competitors
- Khabib explains that Jon Jones had competitive longevity advantages by fighting at light heavyweight and heavyweight, where age is less punishing than in lighter divisions
- Khabib contends that at lightweight and welterweight divisions, the difference in athletic capability between a 32-year-old and 38-year-old fighter is dramatic due to the need for superior reaction speed
Topics
Transcript
[0:03] A lot of people say you're number one, the greatest of all time. Do you think Islam has a chance to become the greatest MMA fighter of all time? >> Well, I've never said that, and I never set out to become number one or to become the greatest athlete and so on. I never had that. My goal was always to become the best in my sport, to become a world champion, to prove to myself that I could do it. [0:33] But it's hard to choose just one person. Even now, look, there's always going to be St. Pierre, there's always going to be Demetrious Johnson, there's always going to be Jon Jones, there's always going to…
Full transcript available for MurmurCast members
Sign Up to AccessMore from Lex Clips
Do antipsychotic drugs work? | Andrew Scull and Lex Fridman
Andrew Scull discusses the efficacy and serious side effects of antipsychotic drugs, explaining that while they help some patients, many are non-responders, and the medications carry substantial risks including tardive dyskinesia, weight gain, metabolic syndrome, and cognitive dulling. The landmark CATIE study revealed that newer, expensive second-generation antipsychotics are no more effective than older first-generation drugs, with 67-82% of patients dropping out due to inefficacy or intolerable side effects.
Surprising origin of antipsychotic drugs | Andrew Scull and Lex Fridman
Andrew Scull explains how chlorpromazine, an antihistamine synthesized in the 1880s, was accidentally discovered to have psychiatric applications in the 1950s through French Navy lieutenant Alain Laborit's experiments. The drug's rapid adoption was driven by pharmaceutical companies' aggressive marketing to politicians and hospital administrators rather than by psychiatrists' initial enthusiasm, transforming it from a 'major tranquilizer' into the first 'antipsychotic' drug.
Cognitive Behavioral Therapy (CBT) vs Psychoanalysis | Andrew Scull and Lex Fridman
Andrew Scull discusses how clinical psychology and cognitive behavioral therapy (CBT) emerged after WWII as alternatives to psychoanalysis, becoming dominant through better empirical evidence, shorter treatment duration, and federal funding advantages. CBT's symptom-focused approach proved more measurable and reproducible than psychoanalytic theory, though its effectiveness remains limited for serious mental disorders.
Do anti-depressant drugs work? | Andrew Scull and Lex Fridman
Andrew Scull discusses the history and efficacy of antidepressants, particularly SSRIs like Prozac, explaining that while they statistically outperform placebo, the clinical improvement is often marginal and comes with significant side effects including sexual dysfunction and withdrawal difficulties. He also addresses 'diagnostic creep' in psychiatry, where conditions become increasingly broadly defined and diagnosed over time.
How drugs and psycho-pharmacology changed mental health | Andrew Scull and Lex Fridman
Andrew Scull traces the accidental discovery of psychopharmacology, beginning with chlorpromazine's unexpected psychiatric effects in the 1950s, and discusses how pharmaceutical companies transformed mental health treatment while also introducing serious side effects like tardive dyskinesia and metabolic complications that remain inadequately addressed.